
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is well positioned for future growth with its pipeline of new products such as the Mobi Tubeless patch pump. This, combined with a transition to a PayGo model and expected growth in the pharmacy channel, is expected to drive revenue growth and potential margin expansion. However, the company will need to continue to innovate and secure favorable contracts in a competitive market in order to maintain its success in the long term.
Bears say
Tandem Diabetes Care is experiencing short-term supply chain challenges in its infusion set segment, negatively impacting both its US and international revenue. Additionally, the company's newest pump, the Mobi, is facing delays in FDA approval and is not included in Tandem's 2026 revenue guidance. The company is also in the early stages of transitioning its US business from the traditional DME channel to pharmacy, and while management expects this shift to result in significant revenue growth in 2027 and 2028, there is uncertainty around the conversion timeline and potential impact on near-term revenues.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares